Last week, diabetes headlines were dominated by a new study from the Faustman Lab at Massachusetts General Hospital, published on Wednesday, August 8th on PLoS One, suggesting that a 90-year-old tuberculosis vaccine called BCG might hold promise for people living with type 1 diabetes. “Human Study Reignites Debate Over Controversial Diabetes ‘Cure,’” wrote Reuters. “Diabetes May Be Reversed By Long-Used Vaccine for TB,” proclaimed Bloomberg news.
The U.S. FDA has approved Roche's Lucentis (ranibizumab injection) for the treatment of diabetic macular edema (DME), a sight-threatening eye disease that occurs in people with diabetes. The FDA previously had approved Lucentis to treat wet (neovascular) age-related macular degeneration (AMD), a condition in which abnormal blood vessels grow and leak fluid into the macula. Lucentis also is approved to treat macular edema following retinal vein occlusion...
This summer I met Catherine Price for the first time. I had been looking forward to this meeting for a long time and when we met and hung out I felt as…
A phase I clinical trial, led by Denise Faustman, MD, PhD, director of the Massachusetts General Hospital (MGH) Immunobiology Laboratory, has confirmed that use of a generic vaccine to raise levels of an immune system modulator can cause the death of autoimmune cells targeting the insulin-secreting cells of the pancreas and temporarily restore insulin secretion in human patients with type 1 diabetes.
I went to the eye doctor this morning for my annual check up. I didn’t go to my usual doctor, but to a doctor at the diabetes clinic. I decided to go there…
When Dr. Mariela Glandt, an endocrinologist, volunteered to treat African refugees in Tel Aviv, she had no idea she would meet a type 1 diabetic like Samuel Agant, 28, from South Sudan. Below, Dr. Glandt shares Samuel’s story of living on the streets of Tel Aviv with type 1 diabetes, without a work permit, without food, and without a constant supply of insulin.